InventisBio Co. Ltd. A

The latest monitoring data from third-party institution PaiPaiWang shows that as of July 31, the number of ten-billion-yuan securities private funds reached 157, an increase of 15 from 142 in June, setting a new record high. The State Council has approved in principle the annual forest logging quotas for key forest areas during the 15th Five-Year Plan period, as compiled by the National Forestry and Grassland Administration. The international standard ISO 19991:2026, Fusion technology — Experimental magnetic confinement fusion facilities — Ultrasonic molecular beam injection fueling technology for fusion devices, led by China, has been officially published. Data from the Ministry of Industry and Information Technology shows that in the first half of 2026, China's internet and related service enterprises above designated size achieved over one trillion yuan in internet business revenue. On the corporate front, InventisBio and Merck have signed a cooperation agreement to jointly advance the clinical development of small-molecule drugs in the oncology field. Nanda Optoelectronics has six ArF photoresist products that have passed customer verification and achieved sales, with the current 50-ton capacity not yet fully utilized. Fullhan Microelectronics supplies chips to humanoid robot companies and industrial robot companies. Yuanjie Technology plans to invest approximately 4.268 billion yuan to build a semiconductor technology industrial park project, expanding the production scale of high-end laser chips. Pengling Technology has made phased progress in the liquid cooling field, with energy storage liquid cooling business already delivering, and preliminary cooperation intentions reached in computing center and server liquid cooling. Yaben Chemical plans to raise no more than 841 million yuan through a private placement for innovative pharmaceutical CDMO projects. New Beiyang has won a bid for a project from China Post worth approximately 110 million yuan. Longsys has obtained a commitment letter for a 720 million yuan special stock repurchase loan. On the capital front, on August 11, the main funds in the Shanghai and Shenzhen markets saw a net outflow of 39.872 billion yuan. The auto parts, engineering consulting services, and communication equipment sectors saw the largest net inflows. The new stock Ultra Pure Materials surged 662.24% on its first trading day. The Dragon and Tiger List shows that three institutional seats made a combined net purchase of 767 million yuan.

The Sci-Tech Innovation Board Healthcare ETF Huaxia rose 2.94 percent, pushing toward a sixth consecutive gain. As of 10:15 a.m. on July 6, 2026, the Shanghai Stock Exchange Sci-Tech Innovation Board Biomedical Index jumped 2.88 percent, with constituent Hotgen Biotech up 13.85 percent, InventisBio rising 10.33 percent, and Mabwell Biotech gaining 9.42 percent. In related news, the Sci-Tech Innovation Board accepted IPO applications from 16 biomedical companies in the first half of 2026, significantly higher than in previous years, with eight of those accepted on June 29 and 30 alone. Zhongtai Securities noted that the pharmaceutical sector is currently trading at a valuation trough, and innovative drugs and their supply chain remain the clearest industry trend. The Sci-Tech Innovation Board Healthcare ETF Huaxia closely tracks the Shanghai Stock Exchange Sci-Tech Innovation Board Biomedical Index, which selects 50 larger-cap listed companies in biomedical and related fields on the board as constituents, with the top ten holdings accounting for 51.84 percent of the total.

The pharmaceutical sector rallied strongly during trading on the 6th, with weight-loss drug and innovative drug concepts standing out. Shouyao Holdings and Gan & Lee Pharmaceuticals were among multiple stocks that hit their daily limit up. As of press time, Shouyao Holdings surged by the 20 percent daily limit, Hotgen Biotech rose about 14 percent, Mabwell Bioscience, InventisBio, and Shanghai Yizhong Pharmaceutical gained over 10 percent, Gan & Lee Pharmaceuticals, Huahai Pharmaceutical, and Menovo Pharmaceutical also hit their daily limit up, BeiGene and Pharmaron climbed over 7 percent, and Hengrui Medicine advanced more than 5 percent. In the Hong Kong market, Duality Biologics, InnoCare Pharma, and Sino Biopharmaceutical rose over 10 percent, while WuXi XDC and Pharmaron gained more than 5 percent. On the news front, the National Medical Products Administration is soliciting public comments on optimizing the review and approval of cell and gene therapy drugs, encouraging clinically value-oriented R&D innovation, focusing on key areas such as malignant tumors and rare diseases, and placing eligible drugs into a 30-day review and approval pathway. Meanwhile, the overseas expansion of innovative drugs is accelerating. Since 2026, the total value of China's innovative drug license-out deals has reached 94.3 billion US dollars, up 81 percent year-on-year, with upfront payments reaching 5.5 billion US dollars, up 124 percent year-on-year, reflecting growing overseas recognition of China's innovative drug pipeline. CICC noted that leading innovative drug companies are shifting from the R&D investment phase into a positive cycle of commercial scale-up and overseas licensing revenue realization.